UY23657A1 - Procedimiento para la preparacion de derivados de indol - Google Patents

Procedimiento para la preparacion de derivados de indol

Info

Publication number
UY23657A1
UY23657A1 UY23657A UY23657A UY23657A1 UY 23657 A1 UY23657 A1 UY 23657A1 UY 23657 A UY23657 A UY 23657A UY 23657 A UY23657 A UY 23657A UY 23657 A1 UY23657 A1 UY 23657A1
Authority
UY
Uruguay
Prior art keywords
preparation
alkyl
indeol
derivatives
procedure
Prior art date
Application number
UY23657A
Other languages
English (en)
Inventor
William Oxford Alexander
Darko Butina
Richard Owen Martin
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB878719167A external-priority patent/GB8719167D0/en
Priority claimed from GB888814002A external-priority patent/GB8814002D0/en
Priority claimed from GB888814481A external-priority patent/GB8814481D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of UY23657A1 publication Critical patent/UY23657A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta invención se refiere a derivados de indol, a procesos para su preparación, a composiciones farmacéuticas que los contienen y a su uso médico, en particular, a compuestos y composiciones para uso en el tratamiento de migrañas, dolor de cabeza enjambrado, hemicránea paroxismal crónica y dolor de cabeza asociado con desórdenes vasculares. Procedimiento para la preparación de un compuesto de la fórmula (I), en donde: R1 y R2 representan independientemente H ó alquilo con 1 a 6 átomos de carbono; R3 representa H; R4 representa H o alquilo con 1 a 3 átomos de carbono; así como sus sales y solvatos farmacéuticamente aceptables (por ejemplo hidratos). Por ejemplo: N,N-dimetil-3-(1-metil-4-piperidinil)-H-indol-5-etansulfonamida. Un ejemplo para el procedimiento de obtención del compuesto de fórmula (I), en otros es: reducir un compuesto de la fórmula (II), en donde R1, R2, R3 y R4 tienen los significados dados anteriormente.
UY23657A 1987-08-13 1993-09-23 Procedimiento para la preparacion de derivados de indol UY23657A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB878719167A GB8719167D0 (en) 1987-08-13 1987-08-13 Chemical compounds
GB888814002A GB8814002D0 (en) 1988-06-14 1988-06-14 Chemical compounds
GB888814481A GB8814481D0 (en) 1988-06-17 1988-06-17 Chemical compounds

Publications (1)

Publication Number Publication Date
UY23657A1 true UY23657A1 (es) 1994-02-25

Family

ID=27263551

Family Applications (1)

Application Number Title Priority Date Filing Date
UY23657A UY23657A1 (es) 1987-08-13 1993-09-23 Procedimiento para la preparacion de derivados de indol

Country Status (28)

Country Link
US (1) US4997841A (es)
EP (1) EP0303507B1 (es)
JP (1) JPH0633252B2 (es)
KR (1) KR0131327B1 (es)
AT (1) ATE92057T1 (es)
AU (1) AU611469B2 (es)
CA (1) CA1310968C (es)
CY (1) CY1728A (es)
CZ (1) CZ404291A3 (es)
DE (2) DE3882614T2 (es)
DK (1) DK172696B1 (es)
ES (1) ES2058292T3 (es)
FI (1) FI92397C (es)
GB (1) GB2208646B (es)
HK (1) HK86793A (es)
HU (1) HU211576A9 (es)
IE (1) IE61488B1 (es)
IL (1) IL87437A0 (es)
LU (1) LU90160I2 (es)
LV (1) LV5736B4 (es)
NL (1) NL970035I2 (es)
NO (2) NO174052C (es)
NZ (1) NZ225820A (es)
PH (1) PH24976A (es)
PT (1) PT88255B (es)
SG (1) SG65393G (es)
SK (1) SK281495B6 (es)
UY (1) UY23657A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8819024D0 (en) * 1988-08-10 1988-09-14 Glaxo Group Ltd Chemical compounds
GB8903036D0 (en) * 1989-02-10 1989-03-30 Glaxo Group Ltd Chemical compounds
IL98392A (en) * 1990-06-07 1996-01-19 Wellcome Found History of indole, their preparation and the pharmaceutical preparations containing them
DK152090D0 (da) * 1990-06-22 1990-06-22 Lundbaek A S H Piperidylsubstituerede indolderivater
US5643784A (en) * 1990-12-04 1997-07-01 H, Lundbeck A/S Indan derivatives
NZ243065A (en) 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
TW222631B (es) * 1991-07-15 1994-04-21 Duphar Int Res
GB9209882D0 (en) * 1992-05-07 1992-06-24 Glaxo Lab Sa Compositions
GB9211277D0 (en) 1992-05-28 1992-07-15 Glaxo Group Inc Pharmaceutical compositions
AU675964B2 (en) * 1992-08-05 1997-02-27 John Wyeth & Brother Limited Amide derivatives
GB9320115D0 (en) * 1993-09-29 1993-11-17 Glaxo Group Ltd Process
US5521196A (en) * 1994-10-05 1996-05-28 Eli Lilly And Company 5-HT1F agonists for the treatment of migraine
US5521197A (en) * 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
FR2731222A1 (fr) * 1995-03-02 1996-09-06 Pf Medicament Nouveaux derives de piperazine aminoindoles cycliques, leur procede de preparation et leur utilisation a titre de medicaments
FR2731224B1 (fr) * 1995-03-02 1997-05-30 Pf Medicament Nouveaux derives bi-tryptaminiques sulfonamides, leur procede de preparation et leur utilisation a titre de medicaments
MX9706969A (es) * 1995-03-20 1997-11-29 Lilly Co Eli 3-(1,2,3,6-tetrahidropiridin-4-il)-1h-indoles y 3-(piperidin-4-il)-1h-indoles sustituidos en la posicion 5: agonistas del 5-ht1f novedosos.
WO1997033579A1 (en) * 1996-03-13 1997-09-18 Glaxo Group Limited Medicaments comprising 5ht1-like receptor agonists with an increased absorption
AR013669A1 (es) * 1997-10-07 2001-01-10 Smithkline Beecham Corp Compuestos y metodos
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US6066092A (en) * 1997-11-06 2000-05-23 Cady; Roger K. Preemptive prophylaxis of migraine device and method
AU2001281738B2 (en) 2000-07-21 2006-12-21 H.Lundbeck A/S Indole derivatives useful for the treatment of cns disorders
WO2003079972A2 (en) 2002-02-22 2003-10-02 New River Parmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
ATE374192T1 (de) * 2000-11-29 2007-10-15 Lilly Co Eli 1-(2-m-methansulfonamidophenylethyl)-4-(m- trifluoromethylphenyl)piperazine und ihre akzeptablen pharmazeutischen salze und solvate und ihre verwendung zur behandlung von inkontinenz
US8329734B2 (en) 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
EP1644004A4 (en) 2003-06-20 2010-10-06 Ronald Aung-Din LOCAL THERAPY FOR THE TREATMENT OF MIGRAINS, MUSCLE CLARIFICATIONS, MUSCLE SPASMS, SPASTICITY AND RELATED CONDITIONS
CN103860540A (zh) * 2004-11-24 2014-06-18 爱尔康公司 奥洛他定在治疗鼻子过敏或发炎状态的制剂制备中的用途
JP2010507585A (ja) * 2006-10-19 2010-03-11 オースペックス・ファーマシューティカルズ・インコーポレイテッド 置換インドール
WO2008056378A2 (en) * 2006-11-09 2008-05-15 Natco Pharma Limited Novel process for the preparation of naratriptan hydrochloride
WO2008072257A2 (en) * 2006-12-12 2008-06-19 Ind-Swift Laboratories Limited Process for the preparation of indole derivatives
WO2009016466A2 (en) * 2007-07-30 2009-02-05 Orchid Chemicals & Pharmaceuticals Limited A process for the preparation of naratriptan hydrochloride
WO2009118753A2 (en) * 2008-03-07 2009-10-01 Usv Limited Process for preparation of naratriptan hydrochloride
WO2010005507A1 (en) 2008-06-30 2010-01-14 Afgin Pharma, Llc Topical regional neuro-affective therapy
WO2010004580A2 (en) * 2008-07-11 2010-01-14 Ind-Swift Laboratories Limited Process for preparing indole derivatives
WO2010084507A2 (en) * 2008-07-15 2010-07-29 Sun Pharmaceutical Industries Ltd. Process for the preparation of n-methyl-2-[3-(1-methyl-4-piperidyl)-1h-indol-5-yl]-ethanesulfonamide and its acid addition salts
WO2011021000A2 (en) 2009-08-20 2011-02-24 Cipla Limited A process for the synthesis of naratriptan
CN102276581B (zh) * 2011-08-05 2013-06-12 上海师范大学 N-取代四氢吡啶连吲哚类化合物及其制备方法及应用
BR112017018944A2 (pt) 2015-03-02 2018-05-15 Afgin Pharma Llc método de tratamento de um estado ou condição de doença em humanos com um medicamento carbinóide, e, método de tratamento de um estado ou condição de doença em um mamífero diferente de um humano com medicamento(s) carbinóide(s)
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
EP3766483A1 (en) 2019-07-19 2021-01-20 BioPharma Synergies, S. L. Orodispersible powder composition comprising a triptan

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2362628A1 (fr) * 1976-08-26 1978-03-24 Roussel Uclaf Nouveaux derives du piperidyl-indole et leurs sels, procede de preparation et application a titre de medicaments
FR2421899A1 (fr) * 1978-01-16 1979-11-02 Roussel Uclaf Nouveaux derives du tetrahydropyridinyl-indole et leurs sels, le procede de preparation et l'application a titre de medicaments de ces nouveaux produits
GR79215B (es) * 1982-06-07 1984-10-22 Glaxo Group Ltd
FR2533924A1 (fr) * 1982-10-05 1984-04-06 Roussel Uclaf Nouveaux derives du 4-(1h-indol-3-yl)a-methyl piperidine-1-ethanol, leurs sels, le procede de preparation, l'application a titre de medicaments et les compositions les renfermant
GB8332435D0 (en) * 1983-12-06 1984-01-11 Glaxo Group Ltd Chemical compounds
GB8332437D0 (en) * 1983-12-06 1984-01-11 Glaxo Group Ltd Chemical compounds
DE3419935A1 (de) * 1984-05-28 1985-11-28 Merck Patent Gmbh, 6100 Darmstadt Verwendung von hydroxyindolderivaten bei der senkung des blutdrucks
GB2162522B (en) * 1984-08-01 1988-02-24 Glaxo Group Ltd An indole derivative
US4548939A (en) * 1984-10-01 1985-10-22 Janssen Pharmaceutica N. V. 1H-Indol-3-yl containing 1,3-dimethyl-1H-purine-2,6-diones
SE8505715L (sv) * 1984-12-04 1986-06-05 Glaxo Group Ltd Indolderivat
IE58370B1 (en) * 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
GB8819024D0 (en) * 1988-08-10 1988-09-14 Glaxo Group Ltd Chemical compounds
GB8903036D0 (en) * 1989-02-10 1989-03-30 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
CZ404291A3 (en) 1993-04-14
US4997841A (en) 1991-03-05
GB8819200D0 (en) 1988-09-14
PT88255A (pt) 1989-06-30
SG65393G (en) 1993-08-06
PT88255B (pt) 1995-03-01
NO174052C (no) 1994-03-09
NO883587D0 (no) 1988-08-12
FI883744A0 (fi) 1988-08-12
KR0131327B1 (en) 1998-04-17
IE882477L (en) 1989-02-13
EP0303507B1 (en) 1993-07-28
NL970035I1 (nl) 1997-11-03
SK404291A3 (en) 2000-09-12
PH24976A (en) 1990-12-26
EP0303507A2 (en) 1989-02-15
IE61488B1 (en) 1994-11-02
FI883744A (fi) 1989-02-14
FI92397C (fi) 1994-11-10
NO174052B (no) 1993-11-29
LV5736A4 (lv) 1996-06-20
DE19775082I2 (de) 2006-04-27
ATE92057T1 (de) 1993-08-15
DK455488D0 (da) 1988-08-12
FI92397B (fi) 1994-07-29
SK281495B6 (sk) 2001-04-09
HU211576A9 (en) 1995-12-28
CY1728A (en) 1994-05-06
JPH01207288A (ja) 1989-08-21
DK455488A (da) 1989-02-14
LU90160I2 (fr) 1998-01-14
JPH0633252B2 (ja) 1994-05-02
AU611469B2 (en) 1991-06-13
NO883587L (no) 1989-02-14
KR890003731A (ko) 1989-04-17
NO1998008I1 (no) 1998-02-05
DE3882614D1 (de) 1993-09-02
CA1310968C (en) 1992-12-01
GB2208646A (en) 1989-04-12
HK86793A (en) 1993-08-27
IL87437A0 (en) 1989-01-31
NL970035I2 (nl) 1998-01-05
AU2069288A (en) 1989-02-16
EP0303507A3 (en) 1990-09-19
NZ225820A (en) 1990-09-26
DK172696B1 (da) 1999-05-31
LV5736B4 (lv) 1997-06-20
GB2208646B (en) 1991-06-26
DE3882614T2 (de) 1993-11-18
ES2058292T3 (es) 1994-11-01

Similar Documents

Publication Publication Date Title
UY23657A1 (es) Procedimiento para la preparacion de derivados de indol
DK391289A (da) Indolderivater
DE69004989D1 (de) Indolderivate.
MY103509A (en) Indole derivatives.

Legal Events

Date Code Title Description
VENC Patent expired

Effective date: 20131015